By PPN News Staff
The FDA approved L-glutamine oral powder (Endari, Emmaus Life Sciences) to reduce the severe complications of sickle cell disease (SCD) in adult and pediatric patients aged 5 years and older.
L-glutamine reduces oxidant damage to red blood cells by improving the redox potential of nicotinamide adenine dinucleotide (NAD), a coenzyme that has been identified as the primary regulator of oxidation.